BLCO icon

Bausch + Lomb

14.94 USD
--0.20
1.32%
At close Updated Oct 31, 4:00 PM EDT
Pre-market
After hours
15.03
+0.09
0.6%
1 day
-1.32%
5 days
-3.55%
1 month
-0.86%
3 months
9.61%
6 months
29.24%
Year to date
-17%
1 year
-26.33%
5 years
-25.3%
10 years
-25.3%
 

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,500

0
Funds holding %
of 7,505 funds
0
Analysts bullish %
of 7 analysts
0
Positive news %
of 5 articles
Price charts implemented using Lightweight Charts™